Luxceptar:

Withdrawal of the marketing authorisation application

viable T-cells

Overview

Kiadis Pharma Netherlands B.V. withdrew its application for a marketing authorisation of Luxceptar for the treatment of patients with blood cancers who are receiving a type of blood stem cell transplant.

The company withdrew the application on 6 November 2019.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Luxceptar (viable T-cells) (PDF/77.25 KB)


    First published: 15/11/2019
    EMA/603662/2019

  • Key facts

    Name
    Luxceptar
    Product number
    EMEA/H/C/002397
    International non-proprietary name (INN) or common name
    • viable T-cells
    Active substance
    • viable T-cells
    Date of withdrawal
    06/11/2019
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating
    Average
    1 rating